Avantor, Inc. (NYSE:AVTR) Shares Acquired by American Trust

American Trust increased its stake in Avantor, Inc. (NYSE:AVTR) by 45.1% during the first quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 13,261 shares of the company’s stock after acquiring an additional 4,121 shares during the quarter. American Trust’s holdings in Avantor were worth $339,000 at the end of the most recent quarter.

A number of other hedge funds have also modified their holdings of the stock. Graypoint LLC boosted its position in shares of Avantor by 3.8% in the first quarter. Graypoint LLC now owns 11,414 shares of the company’s stock worth $292,000 after buying an additional 423 shares during the period. Vontobel Holding Ltd. boosted its position in shares of Avantor by 2.0% in the fourth quarter. Vontobel Holding Ltd. now owns 30,215 shares of the company’s stock worth $690,000 after buying an additional 591 shares during the period. Tokio Marine Asset Management Co. Ltd. boosted its position in shares of Avantor by 3.8% in the fourth quarter. Tokio Marine Asset Management Co. Ltd. now owns 18,725 shares of the company’s stock worth $427,000 after buying an additional 685 shares during the period. Fifth Third Bancorp boosted its position in shares of Avantor by 125.3% in the fourth quarter. Fifth Third Bancorp now owns 1,248 shares of the company’s stock worth $28,000 after buying an additional 694 shares during the period. Finally, Mackenzie Financial Corp boosted its position in shares of Avantor by 1.6% in the fourth quarter. Mackenzie Financial Corp now owns 46,610 shares of the company’s stock worth $1,064,000 after buying an additional 747 shares during the period. 95.08% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of analysts recently issued reports on AVTR shares. Royal Bank of Canada reissued an “outperform” rating and set a $31.00 price objective on shares of Avantor in a research report on Monday, July 29th. Barclays lifted their price objective on Avantor from $25.00 to $28.00 and gave the company an “overweight” rating in a research report on Monday, July 29th. Robert W. Baird lifted their price objective on Avantor from $26.00 to $27.00 and gave the company an “outperform” rating in a research report on Monday, July 29th. TD Cowen raised their target price on Avantor from $28.00 to $31.00 and gave the company a “buy” rating in a report on Monday, July 29th. Finally, Citigroup lowered Avantor from a “buy” rating to a “neutral” rating and cut their target price for the company from $30.00 to $23.00 in a report on Wednesday, July 10th. Four equities research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $27.21.

Insiders Place Their Bets

In other news, insider Christophe Couturier 10,000 shares of the firm’s stock in a transaction on Tuesday, July 30th. The was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Company insiders own 1.50% of the company’s stock.

Avantor Price Performance

Shares of AVTR traded down $0.90 on Friday, hitting $25.60. The company’s stock had a trading volume of 11,282,011 shares, compared to its average volume of 15,055,082. The company has a market capitalization of $17.40 billion, a PE ratio of 65.64, a PEG ratio of 2.71 and a beta of 1.32. The company has a debt-to-equity ratio of 0.89, a current ratio of 1.59 and a quick ratio of 1.05. Avantor, Inc. has a fifty-two week low of $16.63 and a fifty-two week high of $28.00. The company has a 50 day moving average price of $22.59 and a 200 day moving average price of $23.79.

About Avantor

Avantor, Inc engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.